title: Clinical and biological significance of CD56 antigen expression in acute promyelocytic leukemia.
abstract: The biological significance of CD56 antigen expression in patients with acute promyelocytic leukemia (APL) has been under investigation. We investigated the clinical and biologic features of CD56+APL. In our series, CD56 antigen was positive in 4 of 28 (14%) APL patients. No differences were found regarding age, gender, performance status (PS), initial leukocyte and platelet counts, lactate dehydrogenase (LDH) and fibrinogen (Fbg) levels according to CD56 expression. CD34 antigen was co-expressed in 3 of the 4 patients with CD56+ APL, in contrast to 2 of the 24 patients with CD56- APL (P = .01). Extramedullary relapse occurred in 3 of the 4 patients with CD56+ APL, in contrast to none of the 24 patients with CD56- APL (P = .001). Median remission duration was 4 months in CD56+ APL and was not reached in CD56- APL. The CD56+ population had a shorter remission duration (P < .0001) and disease-free survival (P < .0001). In contrast, no difference was found in overall survival. These results suggested that CD56 expression was associated with the leukemogenetic mutation at the primitive hematopoietic progenitor cell level and extramedullary relapse in APL patients treated with ATRA and chemotherapy.
authors.affiliation: Department of Hematology/Oncology, Iwate Medical University School of Medicine, Morioka, Japan. shigei@iwate-med.ac.jp
authors.forename: Shigeki
authors.initials: S
authors.lastname: Ito
authors.forename: Yoji
authors.initials: Y
authors.lastname: Ishida
authors.forename: Tatsuo
authors.initials: T
authors.lastname: Oyake
authors.forename: Mamiko
authors.initials: M
authors.lastname: Satoh
authors.forename: Yusei
authors.initials: Y
authors.lastname: Aoki
authors.forename: Shugo
authors.initials: S
authors.lastname: Kowata
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Uchiyama
authors.forename: Sanae
authors.initials: S
authors.lastname: Enomoto
authors.forename: Takeshi
authors.initials: T
authors.lastname: Sugawara
authors.forename: Hideharu
authors.initials: H
authors.lastname: Numaoka
authors.forename: Keijiro
authors.initials: K
authors.lastname: Suzuki
authors.forename: Kazunori
authors.initials: K
authors.lastname: Murai
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019002:CD56 Antigen / Q000378:metabolism*; D005260:Female; D005434:Flow Cytometry; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy* / Q000378:metabolism* / Q000601:surgery; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D019002:CD56 Antigen